Browse > Article
http://dx.doi.org/10.5713/ajas.2010.90636

Cytotec Induced Embryotoxicity in Developing Mus musculus  

Naeem, Khadija (Department of Zoology, University of the Punjab)
Ahmad, Naveed (Department of Zoology, University of the Punjab)
Asmatullah, Asmatullah (Department of Zoology, University of the Punjab)
Publication Information
Asian-Australasian Journal of Animal Sciences / v.23, no.10, 2010 , pp. 1282-1290 More about this Journal
Abstract
The study was carried out to assess the developmental abnormalities induced by Cytotec in mice during intrauterine life. Pregnant mice were exposed to a single dose of 0, 0.02, 0.04, 0.06, 0.08 and $0.1{\mu}g$/g BW on day 8 of gestation. Fetuses were recovered on day 18 of gestation. These fetuses were subjected to morphological and morphometric studies. Morphological studies showed abnormalities like anophthalmia, microophthalmia, micromelia and syndactyly. In addition to these, resorptions were also encountered in the higher dose groups. Morphometric analysis showed an overall reduction in body weight, crown rump length, brain and eye circumference, pinna and snout size, length of fore and hind limb and tail size with a significant difference (p<0.001) compared to controls. The outcomes of histological studies revealed some brain defects like hydrocephaly, enlarged third ventricle and undifferentiated ectoneural cells and abnormalities of the heart included right auricle thrombosis and degeneration of trabecular zone.
Keywords
Cytotec; Embryotoxicity; Developmental Anomalies; Mice;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Zieman, M., S. K. Fong, N. L. Benowitz, D. Banskter and P. D. Darney. 1997. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet. Gynecol. 90:88-92.   DOI   ScienceOn
2 Product Information. 2005. $Cytotect^{\circledR}$. Pfizer Inc. New York.
3 Qazi, R. A. 2006. Congenital anomalies associated with failed misoprostol termination of pregnancy. J. Liaquat Uni. Med. Health Sci. 5(3):122-124.
4 Robert, A., J. E. Nezamis and J. P. Phillips. 1967. Inhibition of gastric secretions by prostaglandins. Am. J. Dig. Sci. 12:1073-1076.   DOI
5 Rozenberg, P., S. Chevret, F. Goffinet, I. Durand, Y. Ville, C.Vayssiere, A. Roberto, Z. Lahna, I. Nisand, C. Fisch, P. Chaumet-Riffaud and C. Chastang. 2001. Induction of labor with a viable infant: a randomized clinical trial comparing intra-vaginal dinoprostone. Br. J. Obstet. Gynecol. 108:1256-1262.
6 Shetty, A., P. Danielian and A. Temleton. 2002. Sublingual compared with oral misoprostol in term labor induction: a randomized controlled trial. Br. J. Obstet. Gynecol. 109:645-650.   DOI
7 Shetty, A., I. Livingstone, S. Acharya, P. Rice, P. Danielian and A. Templeton. 2003. Oral misoprostol (100 ${\mu}g$) versus vaginal misoprostol (25 ${\mu}g$) in term labor induction: a randomized comparison. Acta. Obstet. Gynecol. Scand. 82:1103-1106.   DOI   ScienceOn
8 Song, J. 2000. Use of misoprostol in obstetrics and gynecology. Obstet. Gynecol. Surv. 55:503-510.   DOI   ScienceOn
9 Tang, O. S., H. Schweer, H. W. Seyberth, S. W. Lee and P. C. Ho. 2002. Pharmacokinetics of different routes of misoprostol. Hum. Reprod. 17:332-336.   DOI   ScienceOn
10 Uzumcu, A., B. Karaman, G. Toksoy, Z. O. Uyguner, S. Candan, H.Eris, B. Tatli, B. Gechinli, A. Yuksel, H. Kayserili and S.Basaran. 2009. Molecular genetic screening of MBS1 locus on chromosome 13 for microdeletions and exclusion of FGF9, GSH1 and CDX2 as causative genes in patients with Mobius Sybdrome. Eur. J. Med. Genet. 52(5):315-320.   DOI   ScienceOn
11 Jonakait, G. M. and L. Ni. 2009. Progstaglandins compromise basal forebrain cholinergic neuron differentiation and survival: action at EP 1/3 receptors result in AIF induced death. Brain Res. 1285:30-41.   DOI   ScienceOn
12 Jost, A. 1986. New data on the hormonal requirements of the pregnant rabbit: partial pregnancies and fetal abnormalities\ after treatment with a hormonal antagonist at subabortifacient doses. C. R. Acad. Sci. 303(Series III NO. 7):281-284.
13 Khan, R. and H. El-Rafaey. 2003. Pharmacokinetics and adverse effects profile of rectally administered misoprostol in the third stage of labor. Obstet. Gynecol. 101:968-974.   DOI   ScienceOn
14 McEvoy, G. K. 1996. American hospital formulatory service-drug information 96. Bathesda, MD: American Society of Health System Pharmacist Inc. (Plus supplements). p. 2171.
15 Meckstroth, K. R., A. K. Whitaker, S. Bertisch, A. B. Goldberg and P. D. Darney. 2005. Misoprostol administered through epithelial route. Obstet. Gynecol. 108:82-90.
16 Middleton, T., E. Schaff, S. L. Fielding, M. Scahill, C. Shannon, E.Westheimer, T. Wilkinson and B. Winikoff. 2005. Randomized trial of mifepristone and buccal or vaginal menstrual period. Contraception 72:328-332.   DOI   ScienceOn
17 Nopdonrattakoon, L. 2003. A comparison for labor induction: a randomized controlled trial. J. Obstet. Gynecol. Res. 29:87-91.   DOI   ScienceOn
18 Norman, J. E., K. J. Thong and D. T. Baird. 1991. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 338:1233-1236.   DOI   ScienceOn
19 Paungmora, N., Y. Herabutya, P. Prasertsawat and P. Punyavachira. 2004. Comparison of oral and vaginal misoprostol for induction of labor at term: a randomized controlled trial. J. Obstet. Gynecol. Res. 30:358-362.   DOI   ScienceOn
20 Product Information. 2009. $Cytotect^{\circledR}$. Pfizer Australia Private, Limited.
21 Foote, E. F., D. R. Lee, A. Karim, W. F. Keane and C. E.Halstenson. 1995. Disposition of misoprostol and its active metabolite inpatients with normal and impaired renal function. J. Clin. Pharmacol. 35:384-389.   DOI   ScienceOn
22 Ginath, S. and H. Zakut. 2001. Misoprostol-for cervical ripening? Eur. J. Obstet. Gynecol. Reprod. Biol. 99:152-153.   DOI   ScienceOn
23 Goldberg, A. B., B. S. Greenberg and P. D. Darney. 2001. Misoprostol and pregnancy. N. Eng. J. Med. 343:38-48.
24 Gonzalez, C. H., M. J. Marques-Dias, C. A. Kim, S. M. Sugayama,J. A. Dal pizzol, S. M. Huson and L. D. Holmes. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet, 351(9116):1624-1627.   DOI   ScienceOn
25 Henriques, A., A. V. Lourenco, A. Riberiniho, H. Ferreira and L. M. Graca. 2007. Maternal death relate to misoprostol overdose. Obstet. Gynecol. 109:489-490.   DOI
26 Gonzalez, C. H., F. R. Vargas, A. B. Perez, C. A. Kim, D. M. J.Brunoni, Marques-Dias, C. R. Leone, J. Correa Neto, J. C.Llerena and J. C. de Almaida. 1993. Limb deficiency with or without mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am. J. Med. Genet. 47(1):59-64.   DOI   ScienceOn
27 Hemminki, E., T. Luostarinen, E. Pukkala, D. Apter and T. Kakulinen. 2002. Oral contraceptive use before first birth and risk of breast cancer: a case control study. BMC Women’s Health 2:9.   DOI   ScienceOn
28 Ho, P. C., S. W., Ngai, K. L. Liu, G. C. Wing and S. W. Lee. 1997.Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet. Gynecol. 90:735-738.   DOI   ScienceOn
29 Javed, L., M. Maik, N. Jamal, S. Sheikh and F. Farzana. 2004. Mid-trimester termination of pregnancy-comparison of sublingual with vaginal misoprostol. Biomedica 20:56-59.
30 Castleman, L. D., K. T. Oanh, A. G. Hyman, T. Thuy le and B. D.Blumenthal. 2006. Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. Contraception 74:272-276.   DOI   ScienceOn
31 Coelho, K.-E. F. A., M. V. F. Barmento, C. M. Veiga, C. E. Speck-Martins, H. P. N. Safattle, C. V. Castro and N. Niikawa. 2000. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am. J. Med. Genet. 95(4):297-301.   DOI   ScienceOn
32 Collins, P. W. 1990. Misoprostol: discovery, development and clinical applications. Med. Res. Rev. 10:149-172.   DOI   ScienceOn
33 CSGN, 2006. http://www.csgnetwork.com/glossary/html#calculator
34 Dal Pizzol, T. S., F. P. Knop and S. S. Mengue. 2006. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta analysis. Reprod. Toxicol. 22:666-671.   DOI   ScienceOn
35 Dal Pizzol, T. S., M. T. V. Sanseverino and S. S. Mengue. 2008. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad. Saude. Publica 24(6):1447-1453.   DOI
36 Deraedt, R., B. Vannier and R. Fournex. 1985. Toxicological study on RU 486. In: The antiprogestin steroid RU 486 and human fertility control (Ed. E. E. Baulieu and S. J. Segal). New York, Plenum Press. pp. 123-126.
37 Derman, R. J., B. S. Kodkany, S. S. Goudar, S. E. Geller, V. A.Naik, M. B. Bellad, S. Patted, A. Patel, S. Edlavitch and T. Hartwell. 2006. Oral misoprostol in preventing postpartum hemorrhage in resource-poor communities: a randomized controlled trial. Lancet 368:1248-1253.   DOI   ScienceOn
38 El-Rafaey, H., D. Rajasekar, M. Abdalla, L. Calder and A. Templeton. 1995. Induction of abortion with mifepristone (RU 486) and oral and vaginal misoprostol. N. Eng. J. Med., 332:983-987.   DOI   ScienceOn
39 Adair, C. D. and D. F. Lewis. 1998. Labor induction with oral versus vaginal misoprostol: a randomized double-blind trial. Am. J. Obstet. Gynecol. 92:810-813.   DOI   ScienceOn
40 Al-Hussaini, T. 2001. Uterine rupture in second trimester abortion in a grand multiparous woman: A complication of misoprostol and oxytocin. Eur. J. Obstet. Gynecol. Rerpod. Biol. 96(2):218-219.   DOI   ScienceOn
41 Andolina, K. L., J. E. Tolosa, J. M. Monzo, N. S. Roberts and S. Daly. 2003. Oral misoprostol is rapidly absorbed in postpartum women at term. J. Matern. Fetal Neonatal. Med. 14:229-232.   DOI   ScienceOn
42 Berghahn, L., D. Christensen and S. Droste. 2001. Uterine rupture during second trimester abortion associated with misoprostol. Obstet. Gynecol. 98:976-977.   DOI   ScienceOn
43 Carbonell, J. L. L., J. Rodriguez, E. Delagdo, C. Sanchez, F. Vargas, L. Valera, J. Mari, F. Valero, I. Salvador and M. Llorente. 2004. Vaginal misoprostol 800 ${\mu}g$ every 12 h for second-trimester abortion. Contraception 70:55-60.   DOI   ScienceOn
44 Carlan, S. J., D. Blust and W. F. O'Brien. 2002. Buccal versus intravaginal misoprostol administration for cervical ripening. Am. J. Obstet. Gynecol. 186:229-233.   DOI   ScienceOn